Linas S L, Whittenburg D, Parsons P E, Repine J E
University of Colorado Health Sciences Center, Webb Waring Lung Institute, Denver General Hospital.
Kidney Int. 1992 Sep;42(3):610-6. doi: 10.1038/ki.1992.325.
The role of neutrophils (PMN) in acute renal failure (ARF) is controversial. Although the development of acute renal failure (ARF) frequently occurs in situations where there is partial activation of PMN (primed PMN) and mild renal ischemia, the interaction between primed PMN and ischemic organs has not been studied in any biological system. To define the interaction between primed PMN and mild renal ischemia, kidneys were made ischemic for 10 minutes in situ and reperfused by the isolated kidney technique with untreated PMN or PMN primed with low concentrations of lipopolysaccharide (LPS) or phorbol myristate acetate (PMA). We found that primed PMN had no effect on control (non-ischemic) kidneys and that untreated PMN did not cause injury to kidneys previously subjected to mild ischemia. However, addition of primed PMN to mildly ischemic kidneys caused severe injury. To determine the nature of renal injury, ischemic kidneys were reperfused with primed PMN and catalase (CAT) or the elastase inhibitor, Eglin C. In ischemic kidneys reperfused with LPS-primed PMN, Eglin C (but not CAT) was partially protective while in ischemic kidneys reperfused with PMA-primed PMN, CAT (but not Eglin C) was partially protective. Reperfusion with both CAT and Eglin C completely prevented the damaging effects of either LPS- or PMA-primed PMN. In conclusion, addition of primed but not untreated PMN causes ARF in mildly ischemic kidneys by PMN oxidant- and/or protease-mediated mechanisms. This synergism could account for the high frequency of ARF in conditions associated with prerenal azotemia and primed PMN.
中性粒细胞(PMN)在急性肾衰竭(ARF)中的作用存在争议。尽管急性肾衰竭(ARF)的发生常常出现在PMN部分激活(预激活PMN)和轻度肾脏缺血的情况下,但在任何生物系统中,预激活PMN与缺血器官之间的相互作用尚未得到研究。为了明确预激活PMN与轻度肾脏缺血之间的相互作用,通过离体肾脏技术,将肾脏原位缺血10分钟,然后用未处理的PMN或用低浓度脂多糖(LPS)或佛波酯肉豆蔻酸酯(PMA)预激活的PMN进行再灌注。我们发现,预激活PMN对对照(非缺血)肾脏没有影响,未处理的PMN也不会对先前经历轻度缺血的肾脏造成损伤。然而,将预激活PMN添加到轻度缺血的肾脏中会导致严重损伤。为了确定肾脏损伤的性质,用预激活PMN和过氧化氢酶(CAT)或弹性蛋白酶抑制剂埃格林C对缺血肾脏进行再灌注。在用LPS预激活PMN再灌注的缺血肾脏中,埃格林C(而非CAT)具有部分保护作用,而在用PMA预激活PMN再灌注的缺血肾脏中,CAT(而非埃格林C)具有部分保护作用。用CAT和埃格林C同时进行再灌注可完全预防LPS或PMA预激活PMN的损伤作用。总之,添加预激活而非未处理的PMN会通过PMN氧化剂和/或蛋白酶介导的机制在轻度缺血的肾脏中导致ARF。这种协同作用可能解释了在与肾前性氮质血症和预激活PMN相关的情况下ARF的高发生率。